| Overview |
| bs-9845R |
| GDN Polyclonal Antibody |
| WB, IHC-P, IF(IHC-P) |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human GDN/SERPINE2 |
| 301-398/398 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 5270 |
| P07093 |
| Secreted, Extracellular domain |
| Glia derived nexin; Protease inhibitor 7; GDN; GDN_HUMAN; Glia-derived nexin; P17 antibody Peptidase inhibitor 7; Pi-7; Plasminogen activator inhibitor type 1, member 2; PN-1; PN1; PNI; Protease nexin 1; Protease nexin I; Serpin E2; Serpin peptidase inhibitor, clade E nexin, plasminogen activator inhibitor type 1, member 2; SERPINE 2; Serpine2. |
| The serine protease inhibitors (serpins) compose a superfamily of proteins with a diverse set of functions, including the control of blood coagulation, complement activation, programmed cell death and development. Serpins are secreted glycoproteins that contain a stretch of peptide that mimics a true substrate for a corresponding serine protease. Protease nexin-1 (PN-1) is a serpin that inactivates several proteases, including thrombin, urokinase, plasminogen activators (PA) and plasmin. It is involved in tissue remodeling, cellular invasiveness, matrix degradation and tumor growth. PN-1 expression is abundant in the nervous system, where it inhibits thrombin, thereby playing a role in neural injury and repair processes. An imbalance between PN-1 and thrombin may be a contributing factor in the pathology of Alzheimer??s disease. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
| IF(IHC-P) |
1:50-200 |
Powered by Bioz